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ABSTRACT 
 
Aim: This paper describes the outcomes of gastrostomy feeding in patients 
with Crohn’s disease (CD). 
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Methods:  Patients with CD who attended the Royal Hospital for Children, 
Glasgow, and received gastrostomy feeding for at least two years between 
2003-2010, were identified from the clinical database.  The data recorded 
included the anthropometric data, CD phenotype, the surgical technique that 
was used, complications, medication, feed type, median feed, calories, 
volume and clinical outcomes.  
Results: The study identified 16 patients (14 male) who had a gastrostomy 
inserted using a pull technique at a median age of 12.6 years at. Of these two 
required laparoscopic placement.  Short-term complications lasting less than 
one month were experienced by nine (56%) patients and one (6%) 
experienced long-term complications.  Anthropometry significantly improved at 
follow up compared to baseline: at 12 months the body mass index z-score 
was 1.11 (p=0.005) and the weight z-score was 0.19 (p<0.05). At 24 months 
the height z-score was -1.03 (p=0.04).  The daily median volume and calories 
from feeds increased significantly from baseline to post PEG insertion, from 
400-738ml and 705 to 860kcal/day (p< =0.01).  
Conclusion: Gastrostomy feeding for paediatric patients with CD was 
associated with improved nutrition, weight gain and growth outcomes.  
 
Keywords: Anthropometry. Children, Crohn’s disease, Gastrostomy, 
Nutrition. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Key Notes 
 We studied 16 patients who had gastrostomy insertion for Crohn’s 
disease at a median age of 12.6 years and followed them for 24 
months. 
 Our findings showed that this method of feeding for paediatric patients 
with CD was associated with improved nutrition, weight gain and 
growth outcomes.  
 Long-term complications only occurred in one of the 16 patients and 
nine reported short-term complications that lasted less than one month.  
patients reported short term complications lasting < one month. 
 
INTRODUCTION 
Crohn’s disease (CD) is a lifelong relapsing and remitting inflammatory 
condition, which can affect any part of the gastrointestinal tract from the mouth 
to the anus (1).  CD is characterised by areas of patchy, transmural 
inflammation, often leading to granuloma formation.  Although it is a life-long 
condition, it has periods of remission and relapse.  The incidence of CD within 
the paediatric population in Scotland is rising, with a median age at CD 
diagnosis of 9.7 years and inter quartile range (IQR) of 7.6-11.3) (2).  Clinical 
presentation in the paediatric population can be variable.  Abdominal pain is 
usually a prominent feature, alongside persistent or recurrent diarrhoea with 
or without blood.  Other symptoms may include nocturnal stooling, tenesmus, 
lethargy, anorexia and nausea.  Symptoms such as malabsorption, early 
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satiety and poor oral intake, lead to problems with growth delay, delayed 
puberty and malnutrition (3).  Growth failure is one of the most significant 
long-term complications of active CD in the paediatric population (4). 
Diagnosis can be delayed due to the wide variety of presenting symptoms and 
this, combined with the diagnosis often being made peri-pubertally, can lead 
to the development of significant growth issues in some patients.   
Once diagnosed, commonly used treatment options for the induction of 
remission are either corticosteroids or exclusive enteral nutrition (EEN) (5). 
Corticosteroids can have a negative impact on growth by interrupting normal 
pubertal growth patterns, leading to pubertal delay and reduced height 
velocity (5,6).  EEN is now recognised as the first-line treatment for active CD 
and has been shown to induce remission, improve nutritional complications at 
diagnosis such as weight loss, improve inflammatory markers and promote 
growth and mucosal healing (5,7,8).  Evidence to date suggests that the use 
of supplementary  enteral nutrition, once remission has been induced, may be  
an effective method of maintaining remission in some patients (9-11).  
Using enteral nutrition to induce and maintain remission has clear benefits, 
but the low palatability of feeds means that up to up to half of patients on EEN 
require an alternative route of feeding during the primary treatment course 
(12).  The long-term use of a nasogastric tube (NGT) can lead to issues 
around food aversion and body image (13,14).   NGT can also be difficult and 
uncomfortable to pass.  When they are in-situ long-term NGT can lead to 
problems such as oral aversion and localised trauma with frequent passing of 
NGT.  As a result, gastrostomy tubes are frequently used to deliver long -term 
enteral nutrition to patients with CD as well as other chronic diseases (15).  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
There is limited evidence to date on the efficacy and safety of delivering long-
term enteral nutrition in paediatric CD via a gastrostomy tube (14,16,17).  
This study aims to describe and evaluate the outcomes of gastrostomy 
insertion and feeding in patients with CD, including growth outcomes. 
 
PATIENTS AND METHODS 
This study was carried out in The Royal Hospital for Children, Glasgow; all 
patients had been diagnosed with CD using standard diagnostic procedures 
(18).  A prospectively maintained clinical database was used to identify all 
children with CD who had had gastrostomy tubes placed between 2003-2010 
with at least two years of data available before and after gastrostomy 
insertion.  A standardised proforma was created to extract relevant data from 
medical, dietetic and nursing notes and this is available from the authors on 
request.  All data was recorded for each patient at defined treatment intervals: 
diagnosis, 24, 12 and six months before, at the time of the gastrostomy tube 
insertion and six, 12, 24 and more than 24 months after insertion.   
The data collected included anthropometric data, such as weight, height and 
body mass index (BMI). Disease activity was assessed using the physician’s 
global assessment (12,18).  The Montreal classification, which was an 
appropriate scoring method at the time of the data collection, was used to 
classify the location and behaviour of CD at the time of fitting the gastrostomy 
(19).  Information was collected regarding any macroscopic or microscopic 
gastric manifestations of CD at the time of gastrostomy insertion.  The surgical 
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technique used at insertion was recorded along with any associated 
complications, which were defined as short-term if they resolved within one 
month of insertion or long-term if they lasted after this period.  Information was 
collected regarding concurrent medication at each time period, along with the 
type of feed and the median volume of feed and calories received.  Pubertal 
status was assessed using Tanner staging (20).  Where available, information 
was collected regarding inflammatory and haematological values at each time 
point.  This included haemoglobin, platelets, erythrocyte sedimentation rate, 
C-reactive protein and albumin levels.  Previous surgery was also 
documented.   
Statistical analysis was conducted using Minitab software version 15 (Minitab 
Ltd, Coventry, UK).  Body weight, height and BMI were first converted to z-
scores according to 1990 UK reference data (21).  Analysis of variance 
(ANOVA) of repeated measurements and Bonferroni’s post-hoc corrections 
were performed for body weight, BMI, height z-scores and inflammatory 
markers with the comparison point set as the time of gastrostomy insertion 
(T+0).  The Mann-Whitney test was used for the comparison of non-
parametric data.  Fisher’s exact test, where needed, was performed using 
Graph Prism version 15 (GraphPad software Inc, California, USA).   
A previous audit of clinical practice identified that no formal ethical approval 
was needed for this type of study.   
RESULTS 
Patient demographics and disease classification 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Over the course of the study period, 19 patients had gastrostomy insertion.  
Three of these were excluded from further analysis as the gastrostomy was 
inserted primarily for an existing significant co-morbid condition not primarily 
CD. These related to one renal condition, one case of cystic fibrosis and one 
patient with a pre-existing feeding condition.  Of the remaining 16 patients, 14 
were male (87.5%).  The disease phenotypes are shown in Table 1.  The 
median age at CD diagnosis was 9.7 years (IQR 7.6-11.3) and the median 
age for gastrostomy insertion was 12.6 years (IQR 9.5-14.0).  The patients 
were followed up for a median of 2.3 years (IQR 0.3-6.5) following 
gastrostomy insertion.   
 
Gastrostomy insertion, disease and complications 
At the time of gastrostomy insertion, two patients had both macroscopic and 
microscopic gastric CD, two patients just had histological evidence of gastric 
CD, 10 patients (62.5%) had non-specific chronic inflammation on gastric 
biopsy at the time of insertion and one patient had normal gastric mucosa. No 
macroscopic assessment or biopsies were obtained for one patient. 
Of the 16 patients, 14 (87.5%) had the gastrostomy insertion endoscopically 
with the remaining two patients having it placed laparoscopically.  A 15fr 
Freka percutaneous endoscopic gastrostomy (PEG) tube (Fresenius-Kabi, 
Cheshire, UK), was used in 12 (75%) of the 16 patients, two (12.5%) had 9fr 
Freka (Fresenius-Kabi) and two (12.5%) had 16fr Corflo PEG (Halyard, 
Surrey, UK).  Six patients (37.5%) received peri-procedural antibiotics. We 
also noted that 12 (75%) of the patients had their PEG tube changed to a 
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lower profile button gastrostomy device at a median of 16 (6-20) months after 
PEG insertion. 
Short-term complications were reported in nine patients, with seven (77%) of 
these experiencing more than one complication.  The complications reported 
include pain at the insertion site (57%), six (66%) reported over granulation, 
six (66%) reported a wound infection around the site that required treatment 
using oral and topical antibiotics and three (33%) patients reported problems 
with leakage.  Only one patient reported long-term complications.  This patient 
had multiple complications, including over-granulation, leakage, pain and 
infection.  We found that six (37%) patients had no complications recorded 
following gastrostomy insertion. 
The majority of patients (10/16, 62%) of patients had not undergone any 
surgery prior to gastrostomy placement.  Of those that underwent surgery, 
2/16 (12%) underwent a right hemicolectomy at the time of gastrostomy 
insertion and the remaining 4/16 (26%) had surgery prior to gastrostomy 
insertion.  The type of surgery prior to gastrostomy insertion included right 
hemicolectomy, ileostomy formation and division of adhesions in one patient.  
The remaining three patients underwent incision and drainage, with packing 
for perianal wound sepsis. 
Anthropometric data and pubertal status 
Table 2 displays the anthropometric data of the study patients pre and post 
PEG insertion.  ANOVA with Bonferroni post-hoc correction demonstrated a 
significant increase in BMI z-scores (p=0.005) at six months post insertion and 
both body weight z-scores (p=0.03) and BMI z-scores (p=0.04) at one year 
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post insertion.  The height z-score improved significantly compared to 
baseline at two years post insertion (p=0.04) and at greater than two years 
post insertion maximal follow up (p=0.03).  No statistical significant differences 
were observed at any other time points.   Figure 1 highlights body weight, BMI 
and height of the 16 patients at the specific time points in the study. 
Detailed pubertal information was available for 11/16 patients.  All patients 
were pre pubertal at the time of the gastrostomy insertion. The majority of 
patients (8/11, 73%) remained pre pubertal with no further significant pubertal 
progression noted two years after insertion.     
 
Inflammatory markers 
Inflammatory markers were available for 15/16 patients at the specified time 
points in the study.  Platelets were found to decrease significantly by 12 
months after the PEG placement (p=0.02) with no statistical significance 
observed for any other blood markers at specified time points after 
appropriate corrections for multiple testing.   
Enteral nutrition 
All patients had received at least one course of exclusive enteral nutrition 
(EEN) prior to PEG placement.  EEN was received by 9/16 (56%) of patients 
following insertion of the gastrostomy tube.  Supplementary feeds were 
received by 10/16 patients prior to PEG placement and five of these were via 
an NGT and five orally.  Following insertion of the gastrostomy tube, all 
patients received supplemental feeds.   
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Feeds given were either polymeric or elemental formulas.  The specific feed 
choice was at the discretion of the dietetic/medical team.  Polymeric feeds 
given included Modulen IBD (Nestle Health Sciences, Yorkshire, UK), 
Nutrison Energy (SHS Nutricia, Wiltshire, UK), Nutrison Standard (SHS 
Nutricia) and Nutrison Fibre (SHS Nutricia). Liquid supplements included 
Calogen (SHS Nutricia) and Fortijuice (SHS Nutricia).  Elemental feeds used 
were Elemental E028 Extra (SHS Nutricia).  Prior to PEG insertion 6/16 
(37.5%), patients were on elemental feeds, one on polymeric and the 
remaining patients received Modulen IBD (Nestle Health Sciences) via NGT 
for EEN.  After the gastrostomy insertion, 3/16 patients were on elemental 
feeds, 3/16 received Modulen IBD with the remaining 9/16 patients on other 
polymeric feeds.  
The median volume of enteral nutrition delivered per day prior to PEG 
insertion (10/16 pts) was 400ml (range 0-550ml), which increased to 738ml 
(392-1300ml) following gastrostomy insertion (p=0.009). The median daily 
calorie intake prior to gastrostomy insertion was 705kcal (410-1080kcal), 
compared with 860kcal per day post gastrostomy insertion (642-1392kcal) 
(p=0.01).   
Medication 
The medications delivered at each time point are summarised in Table 3.  
Following gastrostomy insertion, the proportion of patients receiving 
methotrexate therapy, infliximab therapy, adalimumab and growth hormone 
increased.   
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DISCUSSION 
This case series summarises the experience and safety of gastrostomy 
insertion for young people with CD.  The results from this study indicate there 
were significant improvements in anthropometry after gastrostomy insertion 
including height z-score at two years and maximum follow up.  The volume 
and calories of supplemental enteral nutrition delivered following gastrostomy 
placement significantly increased compared with that before gastrostomy 
placement.  In terms of safety many patients had some form of minor 
complications in keeping with gastrostomy placements in other disease 
groups (22).  
The results of this current study clarify the findings from other similar studies 
looking at gastrostomy placement in patients with CD.  Cosgrove et al 
summarised their experience of 10 paediatric patients who had gastrostomies 
placed with CD in their centre (17).  They concluded that gastrostomy 
placement was safe in this patient group and reported an improvement in 
height z scores (-1.4 to -1.1, p=0.038) at one year following gastrostomy 
insertion that was similar to our own study, where we showed the same 
improvement but after two years.  A similar paediatric study by Israel et al 
showed improvement in linear growth following placement of gastrostomy in 
16 patients, although the follow-up time period was not clearly stated (13).  In 
their report, all patients resumed normal growth, with eight patients 
demonstrating accelerated catch up growth.  Of note this group received 50-
75% of their estimated average requirements via overnight feeds, which may 
have had an impact on oral feeding due to satiety. However, in the current 
study weight gain coincided with an increase in energy intake and feeds 
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volume, which suggested minimal or no compensation of oral intake.   Both 
these studies demonstrated an improvement in height velocity following a 
period of gastrostomy feeding, suggesting increased energy delivery is 
possible, albeit in different proportions of requirements between the two 
studies. 
Israel et al also reported a low complication rate, with only minor 
complications reported, and they therefore reported that gastrostomy 
placement should be considered safe in this patient group (13).  Mahajan et al 
reported on their findings on gastrostomy placement in both paediatric and 
adult patients with CD. The indications for gastrostomy placement included 
nutrition and gastric decompression following abdominal surgery (23).  They 
reported a higher complication rate in those that had gastrostomy placed for 
decompression versus nutritional support (14% versus 3.5%).  They did not 
make any observations regarding growth and did not differentiate between the 
adult and paediatric populations, thus making specific comparison of their 
results to our patient group difficult.  Anstree et al reported their findings of 
adult patients with CD and gastrostomy placement, their sample size was 
small at nine patients and the duration of follow up was not stated (14).  They 
reported an improvement in BMI in 6/9 patients and no major complications.   
Gastrostomy tube insertion site infection was reported as a minor complication 
in our study, with 28% requiring antibiotics for treatment.  Ahmad et al 
reported that 18% of patients developed wound infection, although the study 
participants had not received any prophylactic antibiotics prior to insertion 
(24).  More recent evidence demonstrates that peri-procedural antibiotics 
reduce the wound infection rate to around 3%, so we now routinely give peri-
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procedural antibiotics to all patients receiving gastrostomies, including those 
with CD, which was not consistently the case during this study period (25,26).  
A significant increase was reported in volume and calorie intake following 
gastrostomy insertion in our series – this increase would be higher still in our 
current patient group as we now predominantly use 1.5kcal/ml feeds in this 
patient group as opposed to E028 or Modulen IBD. Supplementary feeding 
has been shown to be beneficial for maintaining remission, but we are unable 
to clearly determine whether supplemental enteral nutrition played a role in 
remission rates in this patient group (9,10,27,28).  We collected the data 
retrospectively and several patients had significant changes to their 
concomitant medication. This meant we could not estimate the effect 
maintenance feeds were having in isolation.   
In the published literature it is well documented that improving nutritional 
status will have a positive impact on improving growth, but this has not been 
clearly demonstrated in paediatric CD following a short-term course of EEN 
(29,30).  However, it should be noted that age and changes in pubertal status 
should be factored into any improvement in nutritional status, as improved 
nutrition may induce pubertal changes that would result in a growth spurt (13).  
The exact reasons for the improved growth in this patient cohort may result 
from optimised nutritional support, but are likely also to have been impacted, 
at least in part, by other concurrent management changes.   Pubertal 
progression was not documented to be a major factor in the growth 
improvement.  However there were changes in medication, with a 
documented increase in the number of patients receiving methotrexate, 
infliximab and adalimumab therapy, as well as a number of patients receiving 
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growth hormone following gastrostomy insertion.  All of these treatments are 
recognised to have a beneficial impact on linear growth, reflecting that the 
modern management of paediatric CD patients with growth failure is often 
multifaceted and that treatment of this difficult problem does not rely on one 
individual treatment modality but several different approaches in combination 
(4).  
Conclusion 
In conclusion, this study demonstrated that gastrostomy insertion in paediatric 
patients was safe and well tolerated.  Gastrostomy insertion could be a useful 
strategy to promote growth, as well as deliver supplemental enteral nutrition to 
keep patients in remission for as long as possible.  Further research should 
explore the effectiveness of gastrostomy insertion on other aspects of 
nutritional status and growth and the impact on health expenditure using 
multicentre intervention controlled trials. 
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Table 1: Phenotypic classification and disease behaviour in paediatric patients with 
CD undertaking enteral feeding via PEG   
Disease location 
Terminal ileum (L1) 2 TI and Upper GI (L1+L4) - 
Colon (L2) 4 Colon and upper GI (L2+L4) 2 
Ileocolonic (L3) 1 Ileocolonic and upper GI(L3+L4) 6 
Upper GI (L4) 1   
Disease behaviour 
Non-stricturing, non-penetrating(B1) 3 Non-stricturing, non-penetrating and 
perianal(B1p) 
6 
Stricturing(B2) 5 Stricturing and perianal(B2p) 1 
Penetrating(B3) - Penetrating and Perianal(B3p) 1 
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Table 2:   Clinical details of 16 children in the months before the  PEG was fitted (T-24),  (T-12) and (T-6), at the fitting of the PEG(T-0) and in the months after 
the fitting of the PEG (T+6), (T+12),(T+24), >(T+24) 
 
T-24 
 
T-12 
 
T-6 
 
T+0 
 
T+6 
 
T+12 
 
T+24 
 
>T+24 
 
T-24 VS 
T+0 
p value 
T-12 
VS T+0 
p value 
T-6 VS 
T+0 
p value 
T+0 VS 
T+6 
p value 
T-0 VS 
T+12 
p value 
T+0 VS 
T+24 
p value 
T+0 VS 
>T+24 
p value 
Age 
11.09 
 
(10.11, 
12.59) 
11.71 
 
(9.98, 
13.15) 
12.378 
 
(11.01,  
13.66) 
12.631 
 
(9.45  
14.03) 
13.224 
 
(9.54,  
13.90 
13.24 
 
(8.87, 
14.48) 
14.51 
 
(10.25,   
15.42) 
14.32 
 
(12.61,   
16.65 
       
 
Anthropometry 
Weight  
SDS 
-1.39 
 
(-1.69,  
-0.12) 
-1.42 
 
(-1.98,  
-0.31) 
-1.47 
 
(-2.34, -
0.01) 
-2.00 
 
(-2.34, -
0.68) 
-0.86 
 
(-1.40, -
0.28) 
-1.11 
 
(-1.77,  
-0.74) 
-0.96 
 
(-1.93, -
0.62) 
-1.17 
 
(-1.60, 
0.39) 
1.00 0.73 1.00 0.03 0.06 0.24 1.00 
BMI  
SDS 
-0.68 
 
(-1.85,  
-0.05) 
-0.89 
 
(-1.68,   
0.08) 
-1.42 
 
(-1.85,  
-0.10) 
-0.92 
 
(-1.97,  
-0.50) 
-0.12 
 
(-0.58,   
0.61) 
-0.19 
 
(-0.94,   
0.38) 
-0.47 
 
(-1.37,   
0.49) 
-0.76 
 
(-0.95, 
0.44) 
1.00 1.00 
 
1.00 0.005 
 
0.03 0.66 1.00 
Height 
SDS 
-0.85 
 
(-1.78,  
-0.33) 
-1.48 
 
(-2.13,  
-0.88) 
-1.50 
 
(-1.92,  
-0.87) 
-1.85 
 
(-2.32, -
1.10) 
-1.61 
 
(-1.96,  
-0.88) 
-1.44 
 
(-2.03,  
-1.04) 
-1.03 
 
(-2.15,  
-0.43) 
-0.51 
 
(-2.00, -
0.29) 
1.00 0.44 0.63 1.00 0.83 0.04 0.03 
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Table 3: Concomitant medical treatment in children receiving enteral feeding via PEG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug/Treatment 
Time period 
Prior to PEG 
placement 
At PEG 
placement 
Post PEG 
placement 
Exclusive enteral 
nutrition (EEN) 
16 1 9 
Azathioprine/6MP 9 4 7 
Steroid therapy 11 7 10 
Methotrexate therapy 9 9 14 
Infliximab therapy 6 1 6 
Adalimumab therapy 0 0 3 
Growth hormone 1 0 5 
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Figure 1: Changes in height, weight and BMI SDS 24months prior to, and 24 
months after, gastrostomy insertion  
 
 
